Maravai LifeSciences (NasdaqGS:MRVI) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsBernd Brust - CEOChanfeng Zhao - SVP and Chief Scientific OfficerDebra Hart - Head of Investor RelationsDoug Schenkel - Managing DirectorRajesh Asarpota - EVP and CFOConference Call ParticipantsJosh Heinen - Research AnalystJustin Bowers - Equity Research AnalystMatt Hewitt - Senior Research AnalystMatt Larew - Research AnalystMatt Stanton - VP and Equity Research AnalystMatthew Parisi - Research Ana ...

经济观察网 根据2026年2月19日的公开信息，莫德纳（MRNA）采用mRNA技术的流感疫苗上市申请已 获得美国食品药品监督管理局（FDA）受理，审批截止日期定于2026年8月1日。FDA此前于2月10日以 临床试验设计存在缺陷为由拒绝受理该申请，但在后续沟通后改变立场，同意启动审核流程。莫德纳为 加速获批已提出分年龄段的监管路径：为50至64岁人群寻求常规批准，为65岁及以上人群寻求加速批 准，并承诺上市后在老年人群中开展追加研究。若获批，该疫苗计划在2026年晚些时候的流感季面向老 年人群使用。 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The company plans to advance the Phase III clinical trial of its liquid nasal spray influenza vaccine for the age group of 18-59 in 2026 [1] - The company aims to accelerate the development of its HSV-2 mRNA vaccine to strengthen its mRNA technology platform [1]

Core Viewpoint - Moderna reported better-than-expected sales performance of its COVID-19 vaccine in the U.S., leading to fourth-quarter revenue exceeding Wall Street expectations [1][2]. Group 1: Financial Performance - The company's quarterly revenue was $678 million, surpassing the analyst average expectation of $626.1 million [2]. - Moderna has faced financial pressure due to a significant decline in COVID-19 vaccine demand following the pandemic [1]. Group 2: Future Outlook - The company reiterated its expectation for a 10% revenue growth in 2026 [2]. - Moderna is actively developing new products to fill the revenue gap and demonstrate the long-term viability of its mRNA technology [1].

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. announced a strategic decision to acquire 100% control of Nameixin Biotech through a phased capital increase and equity transfer, marking a significant integration of innovative biotech with a mature industrial platform [1][11]. Part 01: Nameixin Biotech - Nameixin, established in 2021, focuses on mRNA vaccine and drug development, emphasizing AI-driven innovation and addressing unmet clinical needs [12][13]. - The founding team has over 20 years of experience in virology, immunology, and vaccine development, with key members having held significant positions in top research institutions and multinational corporations [2][13]. - Nameixin has developed a comprehensive technology platform covering target screening, antigen design, mRNA sequence optimization, LNP delivery system development, and lyophilized formulation processes [13][15]. - The company has applied for 14 invention patents, including one PCT international patent, and has obtained six software copyright registrations [15]. - Nameixin's core product, the RSV mRNA vaccine NR222, received clinical trial approval in December 2024, becoming the first lyophilized mRNA vaccine to enter clinical trials in China [6][17]. Part 02: Kanghua Biological - Founded in 2004, Kanghua is the first company in China to produce and sell human diploid cell rabies vaccines, recognized as a "gold standard" by WHO [7][18]. - The company is transitioning from a single product focus to a multi-product strategy, planning to expand into mRNA, recombinant protein/VLP, polysaccharide protein conjugates, and novel adjuvants [18]. - Kanghua's acquisition by Shanghai Biomedical Investment Fund marks a new development phase, with a 21.91% stake acquired [18][20]. - The company has established a strong academic promotion system covering thousands of disease control centers across China, enhancing its brand influence [19]. Part 03: Collaborative mRNA Vaccine Development - The collaboration between Nameixin and Kanghua aims to create a closed loop in mRNA vaccine development, production, and market access [19]. - Kanghua's existing production and R&D facilities, including a 14,000 square meter lab in Wenjiang, provide a solid foundation for large-scale GMP production and quality management [19]. - The partnership will leverage Shanghai's strategic position to enhance collaboration with universities, research institutions, and clinical organizations, facilitating international research pathways [20][21]. - The integration of Nameixin's innovative technology with Kanghua's industrial capabilities is expected to address long-standing clinical needs and enhance the accessibility of mRNA vaccines [21].

Group 1 - The vaccine sector is experiencing a strong performance, with the medical ETF (159929) gaining 0.43% in the afternoon and surpassing a trading volume of 1.2 billion yuan, exceeding last Friday's total [1][3] - The medical ETF's constituent stocks are mostly in the green, with notable gains in vaccine stocks: Zhifei Biological up over 14%, Watson Bio up over 10%, and Hualan Biological up over 6% [3] - The top ten weighted stocks in the medical ETF account for 42.97% of the index, indicating a concentrated investment in key players within the pharmaceutical sector [7][8] Group 2 - Hualan Biological's subsidiary has received approval for clinical trials of its shingles vaccine, marking a significant breakthrough in its pipeline for preventive medicine, with expectations of increased demand due to an aging population [5] - Yiling Pharmaceutical forecasts a net profit of 1.2 to 1.3 billion yuan for 2025, indicating a turnaround from previous losses and signaling a critical operational inflection point [5] - The development of therapeutic cancer vaccines is entering a breakthrough phase, with mRNA technology leading the shift towards efficient and personalized immunotherapy, offering advantages in production, clinical safety, and strategic flexibility [6]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, specifically highlighting companies like Yuyuan Pharmaceutical and CanSino Biologics for their promising developments in mRNA vaccines [1]. Core Insights - The mRNA vaccine sector is experiencing a breakthrough, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three core competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports personalized treatment approaches [1][4]. - The report identifies a favorable ranking of sub-industries, with innovative drugs, research services, and CXO services being prioritized for investment. High-yield sectors include traditional Chinese medicine and pharmacies [10][11]. - Specific companies are recommended for investment based on various therapeutic angles, including PD1 PLUS, ADC, and small nucleic acids, with notable mentions such as Innovent Biologics, CanSino Biologics, and Yuyuan Pharmaceutical [10][12][13]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a 12.40% increase [4][9]. - Sub-sectors such as pharmaceutical commerce (+4.26%) and raw materials (+2.41%) have performed well, while bioproducts and chemical pharmaceuticals have faced declines [4][9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, indicating survival benefits for patients with platinum-resistant ovarian cancer. Meanwhile, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug [1][4]. Investment Recommendations - The report suggests a diversified investment approach across various therapeutic areas, including: - PD1 PLUS: Focus on companies like 3SBio and Innovent Biologics - ADC: Companies such as InnoCare Pharma and Kintor Pharmaceutical - Small nucleic acids: Recommendations include Frontier Biotechnologies and Yuyuan Pharmaceutical - Traditional Chinese medicine: Companies like Zhaoke Pharmaceutical and Fangsheng Pharmaceutical are highlighted [10][12][13]. Fund Holdings - The report notes a decrease in the proportion of public fund holdings in the pharmaceutical sector, with a total holding of 6.67% as of Q4 2025, down 1.46 percentage points from the previous quarter [17][18]. Company Performance - Specific companies have been highlighted for their market performance, with notable increases in stock prices for companies like *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [9]. This comprehensive analysis provides insights into the current state and future potential of the pharmaceutical and biotechnology industry, emphasizing the importance of mRNA technology and strategic investment in key companies.

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically highlighting companies such as Yuyuan Pharmaceutical and CanSino Biologics for potential investment opportunities [1]. Core Insights - The mRNA vaccine sector is experiencing significant advancements, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three main competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports tailored treatments for cancer patients [1][4]. - The report identifies promising sub-sectors within the industry, ranking them as follows: innovative drugs, research services, CXO, traditional Chinese medicine, medical devices, and pharmacies. It suggests a focus on high-growth areas such as innovative drugs, particularly in small nucleic acid therapies, and high-dividend sectors like traditional Chinese medicine and pharmacies [10][11]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a year-to-date rise of 12.40% [4][9]. - Notable performers in the market include *ST Changyao (+70.37%) and Hualan Biological (+32.21%) for the week, while the worst performers include Kain Technology (-13.83%) and Aidi Pharmaceutical (-13.70%) [9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, which shows survival benefits for patients with platinum-resistant ovarian cancer. Additionally, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug targeting advanced colorectal and gastrointestinal tumors [4]. Investment Recommendations - Specific companies to watch include: - From the PD1 PLUS perspective: 3SBio, Kanyin Biologics, Innovent Biologics, and Zai Lab [11]. - From the ADC perspective: InnoCare Pharma, Kelun-Biotech, and Baillie Gifford [11]. - From the small nucleic acid perspective: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [11]. - From the self-immune perspective: Kangnuo Pharmaceutical, Yifang Biologics, and Yipinhong [11]. - From the innovative drug leaders: BeiGene and HengRui Medicine [11]. - From the CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, and Aopumai [11]. - From the medical device sector: United Imaging Healthcare and Yuyue Medical [11].

Group 1: Clinical Data and Impact - The combination therapy of mRNA-4157 and PD-1 inhibitor pembrolizumab significantly reduces the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients after complete resection, with stable efficacy observed over five years of follow-up [1] - This clinical data is seen as the first long-term survival benefit evidence for mRNA technology in non-infectious diseases, providing a boost to the global cancer immunotherapy field [1] Group 2: mRNA Technology Advantages - mRNA technology allows for the direct translation of specific antigen proteins in the body, inducing a specific immune response, and is considered a third-generation drug development platform [2] - The long-term market potential of mRNA technology is gradually becoming evident, with predictions estimating the global mRNA drug market to reach approximately $18 billion by 2024, potentially growing to over $43 billion in the next decade [2] Group 3: Domestic Companies' Initiatives - Domestic companies are actively laying out their strategies in the mRNA sector, with Ginkgo Bioworks' personalized mRNA cancer vaccine EVM16 having initiated its first human clinical trial in China [3] - Ginkgo Bioworks' vaccine is based on its proprietary AI algorithm system, which has shown the ability to identify both reported and novel tumor antigens [3] Group 4: Key Technological Developments - The nano-delivery system is identified as a critical technological bottleneck in mRNA drug development, significantly affecting drug efficacy and clinical translation [4] - Jitai Technology has developed a liver-targeted LNP delivery system for mRNA encoding bispecific antibodies, which has received orphan drug designation in the U.S. and is currently in clinical development [4] Group 5: Competitive Landscape - Jiachenshihai has multiple technology platforms, including mRNA and self-replicating RNA, and has developed a unique ready-to-use delivery carrier that enhances vaccine accessibility [5] - Other companies such as CSPC Pharmaceutical Group, CanSino Biologics, and Yuyuan Pharmaceutical have also reported their involvement in mRNA technology platforms [5]

Market Overview - U.S. stock futures experienced a decline ahead of the market opening, with the Nasdaq 100 futures down 1.72%, S&P 500 futures down 1.39%, and Dow futures down 1.24% [1] - European stock indices also fell, with the Euro Stoxx 50 index dropping over 1% [1] - Japanese government bond yields surged, with 30-year and 40-year bond yields rising at least 28 basis points, indicating significant selling pressure [1] Geopolitical Events - The market is expected to face a series of geopolitical challenges, particularly with the U.S. Supreme Court's decision on tariff legality pending [2] - President Trump is scheduled to deliver a speech at the Davos summit, which investors will closely monitor for signals regarding the Greenland issue [2] Commodity Market - Spot gold and silver reached historical highs, with gold priced at $4,700 per ounce and silver at $95 per ounce, driven by rising geopolitical tensions [6] Company News - Quantinuum, a quantum computing company, is reportedly moving forward with an IPO, aiming for a valuation of $15 billion to $20 billion and seeking to raise $1.5 billion [8] - GSK announced the acquisition of Rapt Therapeutics for $2.2 billion, with a purchase price of $58 per share, representing a 65% premium over the previous closing price [9] - Applovin's stock fell over 7% following a short report alleging systemic compliance risks and significant financial crimes [10] - Sony plans to divest its television business by forming a joint venture with TCL, where TCL will hold a 51% stake and Sony will hold 49% [12] - Moderna reported that its mRNA cancer therapy, when combined with Merck's Keytruda, reduced the risk of recurrence or death in high-risk melanoma patients by 49% [13]